CJC-1295 vs Ipamorelin: Research Comparison

CJC-1295 operates as a synthetic analogue of growth hormone releasing hormone (GHRH), binding directly to GHRH receptors on pituitary somatotrophs to stimulate growth hormone synthesis and secretion. This compound was designed to extend the half-life compared to natural GHRH, though research indicates its actual half-life remains relatively brief at approximately 0.5 hours. Studies focus on its ability to increase growth hormone release, subsequent IGF-1 elevation, and potential effects on body composition and recovery in research models. Ipamorelin represents a different classification entirely as a growth hormone secretagogue, functioning as a selective agonist of the ghrelin receptor within the growth hormone secretagogue receptor family. Research indicates this compound stimulates pituitary growth hormone release through a distinct pathway whilst demonstrating selectivity that minimises effects on cortisol and prolactin levels. This selective action distinguishes it from other growth hormone secretagogues in research applications. Ipamorelin exhibits a longer half-life of approximately 2 hours compared to CJC-1295. The fundamental mechanistic difference lies in their receptor targets and pathways: CJC-1295 directly mimics natural GHRH signalling, whilst Ipamorelin activates the ghrelin receptor system. Research on CJC-1295 primarily examines its role as a GHRH analogue with extended activity, focusing on growth hormone release patterns and downstream IGF-1 effects. Ipamorelin research emphasises its selective growth hormone secretagogue properties, particularly its ability to stimulate growth hormone without the broader hormonal effects seen with other compounds in this class. Both compounds carry a B-grade evidence classification, indicating limited human trial data. Small studies have demonstrated Ipamorelin's growth hormone stimulating effects with minimal cortisol or prolactin impact, though larger comprehensive studies remain needed. CJC-1295 research similarly requires more extensive investigation to fully characterise its effects and safety profile in research applications. Pharmacologically, the four-fold difference in half-life between these compounds may influence study designs in research settings, with Ipamorelin's longer duration potentially requiring less frequent administration compared to CJC-1295's shorter half-life profile.